 Jose Banchs
Concepts (254)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Echocardiography | 16 | 2021 | 556 | 3.740 |
Why?
| | Heart Diseases | 12 | 2022 | 340 | 2.570 |
Why?
| | Neoplasms | 22 | 2023 | 2153 | 2.440 |
Why?
| | Echocardiography, Transesophageal | 4 | 2019 | 89 | 1.260 |
Why?
| | Ventricular Function, Left | 7 | 2022 | 468 | 1.230 |
Why?
| | Ventricular Dysfunction, Left | 7 | 2022 | 374 | 1.220 |
Why?
| | Heart Ventricles | 7 | 2023 | 725 | 1.220 |
Why?
| | Cardiovascular Diseases | 8 | 2022 | 1795 | 1.040 |
Why?
| | Heart Neoplasms | 3 | 2018 | 49 | 1.030 |
Why?
| | Anthracyclines | 5 | 2022 | 41 | 1.010 |
Why?
| | Antineoplastic Agents | 10 | 2019 | 1950 | 1.000 |
Why?
| | Atrial Flutter | 1 | 2023 | 24 | 0.900 |
Why?
| | Atrial Fibrillation | 3 | 2023 | 338 | 0.860 |
Why?
| | Cardiovascular System | 2 | 2023 | 127 | 0.850 |
Why?
| | Stroke Volume | 7 | 2022 | 513 | 0.810 |
Why?
| | Sarcoma | 3 | 2023 | 137 | 0.790 |
Why?
| | Cardiology | 4 | 2020 | 272 | 0.790 |
Why?
| | Medical Oncology | 5 | 2020 | 229 | 0.760 |
Why?
| | Heart Function Tests | 2 | 2019 | 61 | 0.700 |
Why?
| | Practice Patterns, Nurses' | 1 | 2018 | 14 | 0.650 |
Why?
| | Osteosarcoma | 1 | 2019 | 70 | 0.640 |
Why?
| | Thrombosis | 2 | 2018 | 301 | 0.640 |
Why?
| | Endocarditis | 2 | 2021 | 33 | 0.610 |
Why?
| | Thrombocytopenia | 1 | 2019 | 184 | 0.600 |
Why?
| | Tachycardia, Sinus | 1 | 2016 | 1 | 0.590 |
Why?
| | Diagnostic Imaging | 3 | 2018 | 294 | 0.570 |
Why?
| | Cardiotoxicity | 8 | 2023 | 28 | 0.570 |
Why?
| | Pericardial Effusion | 4 | 2019 | 18 | 0.570 |
Why?
| | Echocardiography, Three-Dimensional | 2 | 2018 | 53 | 0.540 |
Why?
| | Cardiomyopathies | 2 | 2016 | 298 | 0.540 |
Why?
| | Education, Medical, Continuing | 1 | 2016 | 124 | 0.530 |
Why?
| | Recovery of Function | 2 | 2016 | 603 | 0.520 |
Why?
| | Takotsubo Cardiomyopathy | 1 | 2015 | 4 | 0.510 |
Why?
| | Pericarditis | 1 | 2014 | 9 | 0.510 |
Why?
| | Rural Population | 1 | 2018 | 451 | 0.500 |
Why?
| | Fibroma | 1 | 2014 | 20 | 0.490 |
Why?
| | Heart | 4 | 2023 | 630 | 0.480 |
Why?
| | Aortic Aneurysm | 1 | 2014 | 51 | 0.480 |
Why?
| | Radiotherapy | 1 | 2015 | 187 | 0.460 |
Why?
| | Radiation Injuries | 1 | 2015 | 131 | 0.460 |
Why?
| | Breast Neoplasms | 7 | 2022 | 1945 | 0.450 |
Why?
| | Humans | 60 | 2023 | 118066 | 0.450 |
Why?
| | Multimodal Imaging | 4 | 2018 | 100 | 0.430 |
Why?
| | Cardiovascular Infections | 1 | 2012 | 2 | 0.420 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2014 | 189 | 0.420 |
Why?
| | Tongue Neoplasms | 1 | 2012 | 21 | 0.410 |
Why?
| | Vascular Diseases | 1 | 2015 | 241 | 0.410 |
Why?
| | Cardiac Tamponade | 3 | 2016 | 16 | 0.400 |
Why?
| | Tracheoesophageal Fistula | 1 | 2011 | 33 | 0.400 |
Why?
| | Myocarditis | 1 | 2012 | 94 | 0.400 |
Why?
| | Mass Screening | 1 | 2018 | 1048 | 0.390 |
Why?
| | Fluoroscopy | 1 | 2011 | 144 | 0.380 |
Why?
| | Middle Aged | 23 | 2022 | 27434 | 0.380 |
Why?
| | Radiography, Interventional | 1 | 2011 | 113 | 0.380 |
Why?
| | Ultrasonography, Interventional | 1 | 2011 | 155 | 0.360 |
Why?
| | Trastuzumab | 5 | 2016 | 91 | 0.350 |
Why?
| | Female | 32 | 2022 | 61147 | 0.340 |
Why?
| | Male | 28 | 2022 | 57376 | 0.340 |
Why?
| | Quality Improvement | 1 | 2016 | 962 | 0.340 |
Why?
| | Stents | 1 | 2011 | 457 | 0.310 |
Why?
| | Early Diagnosis | 3 | 2018 | 226 | 0.300 |
Why?
| | Coronary Artery Disease | 3 | 2021 | 648 | 0.290 |
Why?
| | Heart Failure | 4 | 2023 | 1967 | 0.290 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2012 | 610 | 0.280 |
Why?
| | Prognosis | 8 | 2023 | 3421 | 0.260 |
Why?
| | Echocardiography, Doppler, Color | 2 | 2015 | 38 | 0.260 |
Why?
| | Risk Factors | 11 | 2023 | 8950 | 0.260 |
Why?
| | Heart Conduction System | 2 | 2015 | 81 | 0.250 |
Why?
| | Predictive Value of Tests | 8 | 2022 | 1850 | 0.250 |
Why?
| | Troponin I | 3 | 2015 | 83 | 0.240 |
Why?
| | Esophageal Neoplasms | 2 | 2020 | 281 | 0.240 |
Why?
| | Circulating MicroRNA | 1 | 2023 | 23 | 0.230 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2019 | 1372 | 0.230 |
Why?
| | Retrospective Studies | 14 | 2022 | 12922 | 0.230 |
Why?
| | Lung Neoplasms | 4 | 2020 | 2214 | 0.220 |
Why?
| | Texas | 4 | 2021 | 186 | 0.220 |
Why?
| | Fatal Outcome | 2 | 2015 | 286 | 0.220 |
Why?
| | Biomarkers | 7 | 2023 | 3564 | 0.210 |
Why?
| | Electrocardiography | 2 | 2015 | 555 | 0.210 |
Why?
| | Mitogen-Activated Protein Kinase 7 | 1 | 2021 | 15 | 0.200 |
Why?
| | Adult | 15 | 2022 | 31230 | 0.200 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2021 | 87 | 0.200 |
Why?
| | Doxorubicin | 3 | 2023 | 300 | 0.200 |
Why?
| | Catheters, Indwelling | 1 | 2021 | 82 | 0.190 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2022 | 94 | 0.190 |
Why?
| | Ultrasonography | 3 | 2015 | 714 | 0.190 |
Why?
| | Aged | 12 | 2022 | 19557 | 0.190 |
Why?
| | Radiation, Ionizing | 1 | 2020 | 73 | 0.190 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2023 | 232 | 0.180 |
Why?
| | Shock, Septic | 1 | 2021 | 187 | 0.180 |
Why?
| | Graft vs Host Disease | 1 | 2021 | 214 | 0.170 |
Why?
| | ROC Curve | 2 | 2021 | 466 | 0.170 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2020 | 963 | 0.170 |
Why?
| | Pericardiocentesis | 1 | 2019 | 10 | 0.170 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2020 | 128 | 0.170 |
Why?
| | Erdheim-Chester Disease | 1 | 2018 | 5 | 0.170 |
Why?
| | Systole | 2 | 2016 | 168 | 0.170 |
Why?
| | Cardiac Imaging Techniques | 1 | 2018 | 13 | 0.160 |
Why?
| | Myxoma | 1 | 2018 | 11 | 0.160 |
Why?
| | Follow-Up Studies | 5 | 2021 | 4571 | 0.160 |
Why?
| | Echocardiography, Doppler | 1 | 2018 | 94 | 0.150 |
Why?
| | Carcinoid Heart Disease | 1 | 2017 | 1 | 0.150 |
Why?
| | Staphylococcus aureus | 1 | 2021 | 394 | 0.150 |
Why?
| | Multiple Myeloma | 1 | 2018 | 88 | 0.150 |
Why?
| | Staphylococcal Infections | 1 | 2021 | 347 | 0.150 |
Why?
| | MicroRNAs | 1 | 2023 | 632 | 0.150 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 155 | 0.140 |
Why?
| | Reproducibility of Results | 2 | 2016 | 2855 | 0.140 |
Why?
| | Academies and Institutes | 1 | 2016 | 44 | 0.140 |
Why?
| | Oligopeptides | 1 | 2018 | 247 | 0.140 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2021 | 535 | 0.140 |
Why?
| | Pericarditis, Constrictive | 1 | 2016 | 3 | 0.140 |
Why?
| | Myocardial Ischemia | 1 | 2018 | 251 | 0.140 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2015 | 668 | 0.140 |
Why?
| | Withholding Treatment | 1 | 2016 | 67 | 0.130 |
Why?
| | Cardiotoxins | 1 | 2015 | 5 | 0.130 |
Why?
| | Clinical Decision-Making | 1 | 2018 | 276 | 0.130 |
Why?
| | Sepsis | 1 | 2021 | 530 | 0.130 |
Why?
| | Thrombolytic Therapy | 1 | 2016 | 116 | 0.130 |
Why?
| | Cardiotonic Agents | 1 | 2016 | 127 | 0.130 |
Why?
| | Ventricular Dysfunction | 1 | 2015 | 15 | 0.130 |
Why?
| | Pulmonary Surgical Procedures | 1 | 2014 | 8 | 0.130 |
Why?
| | Daptomycin | 1 | 2014 | 19 | 0.130 |
Why?
| | Cefazolin | 1 | 2014 | 19 | 0.130 |
Why?
| | Pericardium | 1 | 2015 | 50 | 0.120 |
Why?
| | Carotid Artery Diseases | 1 | 2015 | 58 | 0.120 |
Why?
| | Comorbidity | 3 | 2019 | 1520 | 0.120 |
Why?
| | Dexmedetomidine | 1 | 2014 | 52 | 0.120 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2015 | 358 | 0.120 |
Why?
| | Pulmonary Embolism | 1 | 2016 | 182 | 0.120 |
Why?
| | Survival Rate | 4 | 2021 | 1714 | 0.120 |
Why?
| | Amyloidosis | 1 | 2014 | 40 | 0.120 |
Why?
| | Postoperative Complications | 2 | 2015 | 2230 | 0.120 |
Why?
| | Peroxidase | 1 | 2013 | 167 | 0.110 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2016 | 224 | 0.110 |
Why?
| | Hodgkin Disease | 1 | 2015 | 119 | 0.110 |
Why?
| | Heart Valve Prosthesis | 1 | 2014 | 125 | 0.110 |
Why?
| | Chemoradiotherapy | 1 | 2014 | 199 | 0.110 |
Why?
| | Myocardium | 1 | 2018 | 965 | 0.110 |
Why?
| | Coronary Vessels | 1 | 2015 | 233 | 0.110 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2013 | 131 | 0.110 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2023 | 114 | 0.110 |
Why?
| | Decision Trees | 1 | 2012 | 83 | 0.110 |
Why?
| | Preoperative Care | 1 | 2015 | 332 | 0.110 |
Why?
| | Heart Arrest | 1 | 2016 | 291 | 0.110 |
Why?
| | Radiopharmaceuticals | 1 | 2013 | 194 | 0.110 |
Why?
| | Incidence | 4 | 2021 | 2413 | 0.100 |
Why?
| | Young Adult | 3 | 2019 | 10707 | 0.100 |
Why?
| | Positron-Emission Tomography | 1 | 2013 | 297 | 0.100 |
Why?
| | Hypertension, Pulmonary | 1 | 2023 | 1785 | 0.100 |
Why?
| | Antibiotic Prophylaxis | 1 | 2012 | 99 | 0.100 |
Why?
| | Endocarditis, Bacterial | 1 | 2012 | 37 | 0.100 |
Why?
| | Cardiac Catheterization | 1 | 2015 | 541 | 0.100 |
Why?
| | Aortic Valve | 1 | 2014 | 402 | 0.090 |
Why?
| | Prosthesis Implantation | 1 | 2011 | 141 | 0.090 |
Why?
| | Radiosurgery | 1 | 2013 | 318 | 0.090 |
Why?
| | Risk Assessment | 3 | 2018 | 3041 | 0.090 |
Why?
| | Combined Modality Therapy | 3 | 2018 | 1162 | 0.090 |
Why?
| | Anti-Inflammatory Agents | 1 | 2012 | 467 | 0.080 |
Why?
| | Myocardial Infarction | 1 | 2015 | 966 | 0.080 |
Why?
| | Treatment Outcome | 4 | 2018 | 9311 | 0.080 |
Why?
| | Animals | 5 | 2023 | 33107 | 0.070 |
Why?
| | Aged, 80 and over | 3 | 2015 | 6533 | 0.070 |
Why?
| | Antiviral Agents | 1 | 2012 | 650 | 0.070 |
Why?
| | Sensitivity and Specificity | 1 | 2011 | 1783 | 0.070 |
Why?
| | Palliative Care | 1 | 2012 | 631 | 0.070 |
Why?
| | Prevalence | 1 | 2011 | 2321 | 0.060 |
Why?
| | Troponin | 1 | 2023 | 47 | 0.060 |
Why?
| | Natriuretic Peptide, Brain | 2 | 2015 | 105 | 0.060 |
Why?
| | Adolescent | 2 | 2019 | 18342 | 0.060 |
Why?
| | Anti-Bacterial Agents | 1 | 2012 | 1513 | 0.060 |
Why?
| | Taxoids | 2 | 2013 | 97 | 0.050 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2022 | 54 | 0.050 |
Why?
| | Antigens, CD19 | 1 | 2022 | 96 | 0.050 |
Why?
| | Ribose | 1 | 2021 | 17 | 0.050 |
Why?
| | Adenosine Diphosphate | 1 | 2021 | 83 | 0.050 |
Why?
| | Cyclophosphamide | 1 | 2021 | 221 | 0.050 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2021 | 40 | 0.050 |
Why?
| | Feedback | 1 | 2021 | 152 | 0.050 |
Why?
| | Tertiary Care Centers | 1 | 2021 | 117 | 0.050 |
Why?
| | Ventricular Function, Right | 1 | 2023 | 257 | 0.050 |
Why?
| | Pulmonary Circulation | 1 | 2023 | 423 | 0.050 |
Why?
| | United States | 4 | 2019 | 12477 | 0.050 |
Why?
| | Immunotherapy, Adoptive | 1 | 2022 | 191 | 0.050 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 23 | 0.040 |
Why?
| | Radiotherapy Dosage | 1 | 2020 | 245 | 0.040 |
Why?
| | Exercise Therapy | 1 | 2023 | 355 | 0.040 |
Why?
| | DNA Topoisomerases, Type II | 1 | 2019 | 45 | 0.040 |
Why?
| | Peptide Fragments | 2 | 2015 | 688 | 0.040 |
Why?
| | Immunocompromised Host | 1 | 2021 | 198 | 0.040 |
Why?
| | Multivariate Analysis | 2 | 2014 | 1468 | 0.040 |
Why?
| | Societies | 1 | 2018 | 42 | 0.040 |
Why?
| | Logistic Models | 2 | 2015 | 1894 | 0.040 |
Why?
| | Hemangiosarcoma | 1 | 2018 | 19 | 0.040 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2018 | 71 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2022 | 634 | 0.040 |
Why?
| | DNA Damage | 1 | 2020 | 356 | 0.040 |
Why?
| | Arterial Occlusive Diseases | 1 | 2018 | 74 | 0.040 |
Why?
| | Reference Values | 1 | 2018 | 764 | 0.040 |
Why?
| | Phosphorylation | 1 | 2021 | 1617 | 0.040 |
Why?
| | Program Development | 1 | 2019 | 353 | 0.040 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 353 | 0.040 |
Why?
| | Interprofessional Relations | 1 | 2019 | 260 | 0.040 |
Why?
| | Prospective Studies | 2 | 2022 | 6443 | 0.040 |
Why?
| | Practice Guidelines as Topic | 2 | 2014 | 1434 | 0.040 |
Why?
| | Morbidity | 1 | 2017 | 293 | 0.030 |
Why?
| | Mice | 2 | 2023 | 15425 | 0.030 |
Why?
| | Cytokines | 1 | 2023 | 1879 | 0.030 |
Why?
| | Mitochondria | 1 | 2021 | 785 | 0.030 |
Why?
| | Galectin 3 | 1 | 2015 | 19 | 0.030 |
Why?
| | Recurrence | 1 | 2018 | 969 | 0.030 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2015 | 35 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2015 | 67 | 0.030 |
Why?
| | Breast | 1 | 2015 | 137 | 0.030 |
Why?
| | Global Health | 1 | 2017 | 308 | 0.030 |
Why?
| | Program Evaluation | 1 | 2019 | 834 | 0.030 |
Why?
| | Intraoperative Care | 1 | 2014 | 38 | 0.030 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 1 | 2014 | 29 | 0.030 |
Why?
| | Biopsy | 1 | 2018 | 1073 | 0.030 |
Why?
| | Diastole | 1 | 2015 | 145 | 0.030 |
Why?
| | Secondary Prevention | 1 | 2016 | 227 | 0.030 |
Why?
| | SEER Program | 1 | 2015 | 206 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2020 | 1167 | 0.030 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2014 | 47 | 0.030 |
Why?
| | Ohio | 1 | 2014 | 140 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2015 | 185 | 0.030 |
Why?
| | Europe | 1 | 2014 | 354 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2018 | 960 | 0.030 |
Why?
| | Phenotype | 1 | 2021 | 2916 | 0.030 |
Why?
| | Acute Disease | 1 | 2016 | 933 | 0.030 |
Why?
| | C-Reactive Protein | 1 | 2015 | 364 | 0.030 |
Why?
| | Amyloid | 1 | 2014 | 87 | 0.030 |
Why?
| | Anesthesia | 1 | 2014 | 120 | 0.030 |
Why?
| | Interleukin-1 Receptor-Like 1 Protein | 1 | 2012 | 24 | 0.030 |
Why?
| | Time Factors | 2 | 2013 | 6362 | 0.030 |
Why?
| | Consensus | 1 | 2014 | 531 | 0.030 |
Why?
| | Odds Ratio | 1 | 2015 | 992 | 0.030 |
Why?
| | Action Potentials | 1 | 2015 | 418 | 0.030 |
Why?
| | Disease Management | 1 | 2016 | 567 | 0.030 |
Why?
| | North America | 1 | 2012 | 264 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2015 | 1218 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 837 | 0.020 |
Why?
| | Pilot Projects | 1 | 2016 | 1405 | 0.020 |
Why?
| | Radiology | 1 | 2014 | 198 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2012 | 523 | 0.020 |
Why?
| | Age Factors | 1 | 2018 | 2991 | 0.020 |
Why?
| | Myocardial Contraction | 1 | 2012 | 338 | 0.020 |
Why?
| | Societies, Medical | 1 | 2014 | 700 | 0.020 |
Why?
| | Receptors, Cell Surface | 1 | 2012 | 362 | 0.020 |
Why?
| | Patient Selection | 1 | 2014 | 669 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2015 | 2487 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3160 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 4518 | 0.020 |
Why?
| | Cohort Studies | 1 | 2013 | 5072 | 0.010 |
Why?
|
|
Banchs's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|